CClinicalTrials.gg
TerminatedNCT00837395Updated Apr 28, 2020

Inflammatory Mediators and microRNA Analysis in Premenstrual Asthma

An observational study in Asthma, sponsored by Ohio State University. Terminated at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-28.

Sponsored by Ohio State University · Observational

Why this study was terminated
Co-investigator left the university and another co-investigator died several years ago, making it impossible to complete the study as planned.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
24
Ages
18 Years and older
Sex
Female
01

Study summary

A small number of women with asthma have an increase in asthma symptoms during the premenstrual or menstrual period. This study is being done to investigate the possible causes of this premenstrual increase in asthma symptoms and to help asthma care providers identify those patients who may suffer from this condition.

Read the detailed description

It is well established that women suffer more asthma symptoms and worse health-related quality of life than men with the same level of asthma severity. The etiology for these sex-related differences in unknown, but a subset of women has premenstrual asthma (PMA) with worsening of their asthma symptoms either prior to or during menstruation. Previous small trials have suggested that an increase in the host inflammatory response may correlate with PMA symptoms. We have evidence that small inhibitory ribonucleic acids, microRNAs, circulating in the peripheral blood of human patients may be expressed in different patterns in certain disease states when compared to healthy individuals.

We plan to compare the patterns of microRNA expression in a well characterized group of women with PMA to those without PMA to determine if alterations in these microRNA patterns play a role in increased asthma symptoms in the premenstrual period. In addition, we plan to compare the levels of inflammatory markers in these populations to better define the specific subset of women that may be at risk for premenstrual asthma. By better characterizing these women, we hope to identify clinically relevant predictors that may guide therapy for women who suffer from PMA.

Procedures to be used in this study include questionnaire administration, pulmonary function assessment, exhaled nitric oxide evaluation, urine sampling for pregnancy, and blood draws for microRNA and serum leukotriene evaluation. These techniques are utilized widely in clinical asthma research, and are associated with minimal risk.

02

Conditions studied

  • Asthma

Browse trials for

Keywords

  • premenstrual increase in asthma symptoms
03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's enrollment of 24 is below the median of 150 across 970 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Ohio State University is the lead sponsor of 640 studies on the registry; 144 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 45 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

primary care clinic, community sample

Inclusion criteria

  • Diagnosis of asthma

Exclusion criteria

Exclusion Criteria:

  • Are pregnant
  • Take hormonal medication
  • Have an illness with fever (> 38.0 ˚ C or 100.4 ˚ F) within 24 hours of Visit 1 or between Visits 1 and 2
  • Are participating in another interventional research trial
  • Have other major chronic illnesses that would interfere with participation
  • Are taking the following medications: leukotriene receptor antagonists, oral steroids, anticoagulants, or insulin
  • Are unable to provide consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
24 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • premenstual asthma

    women with asthma have an increase in asthma symptoms during the premenstrual or menstrual period

06

What researchers measure

Primary outcomes

  1. To determine the patterns of serum microRNA in asthmatic women with premenstrual asthma and asthmatic women without premenstrual asthma at baseline and during the premenstrual period

    microRNA patterns in women with premenstrual asthma

    Time frame: during the study

Secondary outcomes

  1. To determine the level of exhaled nitric oxide and serum leukotrienes B4 (LTB4) and C4 (LTC4) in asthmatic women with premenstrual asthma and asthmatic women without premenstrual asthma at baseline and during the premenstrual period

    Inflammatory markers

    Time frame: during the study

07

Study locations

1 site
  • The Ohio State University
    Columbus, Ohio 43210, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00837395
Lead sponsor
Ohio State University
Responsible party
Jennifer McCallister MD (Associate Professor Clinical Internal Medicine, Ohio State University) — Principal investigator
First posted
Feb 5, 2009
Start date
Feb 2009
Primary completion
Dec 2019
Completion
Dec 2019
Last update
Apr 28, 2020

Study contacts

Jennifer McCallister, MD
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion